EUTILEX.CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,260 KRW | -0.88% |
|
+2.03% | -33.14% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 216M 159K 217K | Sales 2023 | 132M 97.29K 132K | Capitalization | 124B 91.82M 125M |
|---|---|---|---|---|---|
| Net income 2022 | -33.43B -24.7M -33.59M | Net income 2023 | -27.72B -20.48M -27.86M | EV / Sales 2022 | 857 x |
| Net cash position 2022 | 59.24B 43.78M 59.54M | Net cash position 2023 | 33.16B 24.51M 33.33M | EV / Sales 2023 | 692 x |
| P/E ratio 2022 |
-5.84
x | P/E ratio 2023 |
-4.48
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.41% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.88% | ||
| 1 week | +2.03% | ||
| Current month | +2.26% | ||
| 1 month | +0.89% | ||
| 3 months | -19.57% | ||
| 6 months | -9.60% | ||
| Current year | -33.14% |
1 week
2 220.00
2 305.00
1 month
2 095.002 305.00
Current year
2 095.003 690.00
1 year
2 095.005 420.00
3 years
2 095.0025 600.00
5 years
2 095.0041 133.33
10 years
2 095.0048 166.67
| Managers | Title | Age | Since |
|---|---|---|---|
Soo-Young Choi
CEO | Chief Executive Officer | 63 | 20-02-29 |
Byoung Kwon
FOU | Founder | 77 | 15-02-26 |
Guk-Hee Lee
AUD | Comptroller/Controller/Auditor | 76 | 16-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong-Sang Cho
BRD | Director/Board Member | 76 | 18-12-27 |
Byoung Kwon
FOU | Founder | 77 | 15-02-26 |
Myung-Hee Han
BRD | Director/Board Member | 76 | 18-12-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 2,260 | -0.88% | 72 444 |
| 24-05-16 | 2,280 | +0.88% | 87,887 |
| 24-05-14 | 2,260 | +1.12% | 74,477 |
| 24-05-13 | 2,235 | 0.00% | 62,697 |
| 24-05-10 | 2,235 | +0.90% | 100,797 |
End-of-day quote Korea S.E., May 16, 2024
More quotes
Eutilex Co., Ltd. is a Korea-based company mainly engaged in the production and sale of immunotherapy products. Major products include anticancer T cell therapies and antibody therapies.
Sector
Pharmaceuticals
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -33.14% | 62.22M | |
| -2.32% | 92.59B | |
| +3.68% | 41.43B | |
| -11.19% | 33.49B | |
| -19.31% | 14.62B | |
| -9.01% | 12.77B | |
| -11.34% | 11.58B | |
| -43.53% | 11.35B | |
| +3.75% | 8.97B | |
| -6.32% | 8.3B |
- Stock Market
- Equities
- A263050 Stock
